Trichostatin A (TSA)

目录号:S1045

Trichostatin A (TSA) Chemical Structure

Molecular Weight(MW): 302.4

Trichostatin A (TSA)是一种HDAC抑制剂,无细胞试验中IC50为1.8 nM左右。

规格 价格 库存 购买数量  
RMB 2022.93 现货
RMB 3660.93 现货
RMB 7125.3 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的6个实验数据:

  • Gck expression in WT primary hepatocytes transduced with FOXO1 and KR-FOXO1 adenoviruses in the presence or absence of trichostatinA (TSA).

    Cell, 2017, 171(4):824-835.e18. Trichostatin A (TSA) purchased from Selleck.

    Effect of TSA, SAHA and silibinin alone and in combination on left panel: IF staining for p-histone H3 Ser 10 and p-MPM-2 Ser /Thr positive cells and a-tubulin for mitotic spindle and DAPI as nuclear stain in H1299 cells. Right panel: % positive p-histone H3 Ser 10 mitotic cells and expression of p-MPM-2 Ser /Thr protein levels in H1299 cells.

    Epigenetics 2012 7(10):1161-72. Trichostatin A (TSA) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

  • (B) The mRNA level of PRRT2 in the presence of different concentrations of DAC and TSA.

    Biochem Biophys Res Commun, 2017, 485(2):454-460. Trichostatin A (TSA) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM TSA was added.

     

     

    2010 Dr. Zhang of Tianjin Medical University. Trichostatin A (TSA) purchased from Selleck.

产品安全说明书

HDAC抑制剂选择性比较

生物活性

产品描述 Trichostatin A (TSA)是一种HDAC抑制剂,无细胞试验中IC50为1.8 nM左右。
靶点
HDAC [1]
(Cell-free assay)
~1.8 nM
体外研究

Trichostatin A 抑制八种乳腺癌细胞系,包括MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, 和 SK-BR-3增殖,平均IC50为124.4 nM (范围为26.4-308.1 nM),作用于表达ERα的细胞系比作用于表达 ERα阴性的细胞系更有效。Trichostatin A作用于全部乳腺癌细胞系,抑制HDAC活性,平均IC50为 2.4 nM (范围为0.6-2.6 nM), 产生显著的组蛋白 H4高度乙酰化。[1]与 Trapoxin (TPX) 和 Chlamydocin 有效抑制HDAC1 或 HDAC4而不是 HDAC6不同,Trichostatin A 抑制这些HDACs,且抑制程度相似, IC50 分别为6 nM, 38 nM, 和8.6 nM。[2] Trichostatin A (100 ng/mL) 作用于MIA PaCa-2细胞,通过招募p300和 PCAF进入Sp1-NF-Y HDAC复合体,而诱导转化生长因子βⅡ型受体(TβRII) 表达,复合体与TβRII 启动子的DNA片段结合,伴随着Sp1乙酰化,且与复合体相关的HDAC数理全部降低。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK 293 NUWzd|VWTnWwY4Tpc44hSXO|YYm= NUS1[4VOOC55zszN M1vpPVI1cA>? MVrleIhidm:u M{nuTIVvcGGwY3XzJGVP[UNiYXPleJlt[XSrb36gZY5lKGmwY4LlZZNmeyCHTnHDJIFjfW6mYX7j[UBqdiC2aHWgeI91[WxiY3XscEBtgXOjdHWgZY5lKGG2IITo[UBk\WyuIIP1doZi[2V? MYSyOVc5PzB5OR?=
TE13 Mlq1SpVv[3Srb36gRZN{[Xl? MlXCNE4{|ryP M4P0bVI1cA>? NETPbmJ2eC2{ZXf1cIF1\XNiUlHTV2Y2SSCuZY\lcC=> MXGyOVU4QTZ4NR?=
TE13 NWO4[HdwSXCxcITvd4l{KEG|c3H5 MVywMlPPxE1? NVXxPXJSOjSq M1GxN4lvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25? NHfzSmQzPTV5OU[2OS=>
MEFs M{m1dWZ2dmO2aX;uJGF{e2G7 NYLrTFdnPc7:TR?= NHLZfYkyPmh? NVfXdpFucW6lcnXhd4V{KHSqZTDFVGVEKGG2dHHjbI1mdnRuIGTpdkBl\WyrdnXyfUBidmRidHjlJIVn\mmlaXXuZ5khd2ZicHXk[ZN1[WxiZn;ycYF1cW:w NHzoWJUzPTR6Mk[zOC=>
SW480  NE\rfoVHfW6ldHnvckBCe3OjeR?= NVvmVZZ7OC5zzszN NEL6cZM1QGh? M3HrdmROW09? M{HTbJJmfmW{c3XzJGVOXA>? MnLyNlU1OzR7OUe=
PC3  M1TqPWZ2dmO2aX;uJGF{e2G7 MorONE4y|ryP MVS0PIg> M3rrR2ROW09? MlzZdoV3\XK|ZYOgSW1V M3LPZ|I2PDN2OUm3
SW480  MXXGeY5kfGmxbjDBd5NigQ>? MlTWNE4y|ryP NGLoNIc1QGh? NIrueGFFVVOR MV7heJRmdnWjdHXzJIlvfmG|aX;uJIFv\CCvaXfyZZRqd25? M1fNPFI2PDN2OUm3
PC3  MoLFSpVv[3Srb36gRZN{[Xl? NEK1eokxNjIQvF2= M4LNW|Q5cA>? NVvD[GNwTE2VTx?= NYCxSZhG[XS2ZX71ZZRmeyCrbo\hd4lwdiCjbnSgcYloemG2aX;u M1vQflI2PDN2OUm3
SW480  NHHjXHRHfW6ldHnvckBCe3OjeR?= MX:wMlHPxE1? NHTzeZo1QGh? NGrBSpRFVVOR NVvUU2hYcW6mdXPld{BqdmO{ZXHz[UBw\iCKRFHDNUBidmRiSFTBR|Ihd25iU3z1[{Bo\W6nczDwdo9ud3Snch?= MWCyOVQ{PDl7Nx?=
PC3  M2q5bWZ2dmO2aX;uJGF{e2G7 MYmwMlHPxE1? NFj6U4U1QGh? NGLGWphFVVOR M4XnVolv\HWlZYOgbY5kemWjc3Wgc4YhUESDQ{GgZY5lKEiGQVOyJI9vKFOudXeg[4Vv\XNicILvcY91\XJ? MWmyOVQ{PDl7Nx?=
A431 NVTiR5RuSXCxcITvd4l{KEG|c3H5 Mn;TNk8yOC93MD:xNFBvVQ>? NEXwVZg1QGh? NF70bXFFVVOR M{jS[4lvcGmkaYTzJJRp\SClZXzsJIdzd3e2aB?= NHXufVAzPTN5MUC2PS=>
A431 NVLpfJU1TnWwY4Tpc44hSXO|YYm= MlvpOVBvVQ>? M13QblIwPi9zMj:yOIg> MY\EUXNQ MUThZ5RqfmG2ZYOgdFIyKGGwZDDpcohq[mm2czDBWGY{KGW6cILld5Nqd25? NFTPdZUzPTN5MUC2PS=>
MDA-MB-231 NVS5XHk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn60NE03ODCwTR?= NHfHWnEzPGh? NYfpW2g4TE2VTx?= NXHOVJRFUUN3MDDv[kAyODCwTR?= MoDxNlUyQTJ5MkG=
MCF7 NXzDRWw3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPyOm8yOC14MEDuUS=> NVmyfoFDOjSq NILZbWRFVVOR NU\GPVB7UUN3MDDv[kA4PW6P Mo\4NlUyQTJ5MkG=
SKOV-3 MnziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY[xMVEx|ryP NX\LXHZ3OjSq NWmyWZdJTE2VTx?= MniyTWM2OCCxZjC1MlbPxE1? NXG4WHZmOjVzNkm0PVE>
A549 M1OwW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPF[XkyNTFyzszN M1v6PVI1cA>? MkflSG1UVw>? NX7HWII4UUN3MDDv[kA{NjMQvF2= NFXJVJYzPTF4OUS5NS=>
SKOV-3 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUSwMlEuOc7:TR?= MlKxOFhp M{\UVmROW09? NYWwdHZLUUN3MDDv[kAxNjgQvF2= MWmyOVE3QTR7MR?=
A549 NWPoPYY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTBRmc3OC5zLUJOwG0> M4nR[FQ5cA>? NV;KfFBrTE2VTx?= NV;6T|NkUUN3MDDv[kAxNjJ6zszN MoiyNlUyPjl2OUG=
SKOV-3 M{naZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUH1Uo5VOC5yMT2wMlnPxE1? NVjBNI5nPzKq M{foN2ROW09? M3\EcWlEPTBib3[gNE4{Os7:TR?= NUTKblZHOjVzNkm0PVE>
A549 MmTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmS1NE4xOS1yLkpOwG0> NYK1W4NzPzKq MUHEUXNQ NVjTemNGUUN3MDDv[kAxNjB4zszN Moq4NlUyPjl2OUG=
HeLa M4ntOmZ2dmO2aX;uJGF{e2G7 MnPxNlUxdk1? M1\y[FE3cA>? NU\5WHdHTE2VTx?= M4fFNYlv[3KnYYPld{BEYVBzQUGgcXJPSSCneIDy[ZN{cW:wwrC= NGi1OYIzPTFzNk[4PC=>
CNE2 M2nnWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXv4SnF3OTByLU[wNI5O MWqyOE81QC95Mni= NGPRN45qdmirYnn0d{B1cGVicILvcIln\XKjdHnvckBqdiCjIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NFPTPHUzPDl4OUmwNS=>
PC3 MnPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPvNVAxNTFyMEDuUS=> MlPQNlRp M2TXW2lEPTBib3[gN|Axdk1? MV:yOFg2PDZ3OB?=
LNCaP NXLQfJdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\YNVAxNTFyMEDuUS=> M4rYN|I1cA>? NHvFU2VKSzVyIH;mJFMxOG6P MU[yOFg2PDZ3OB?=
HeLa  NYixcpF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYD5UodsOs7:TR?= MoC1OFhp MYjk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliYXLveZQhOjVn MV:yOFg1PjF|NR?=
HMEC-1  M2DWUGZ2dmO2aX;uJGF{e2G7 MWOzNFBvVQ>? NWfI[mQyOjSq M2DlUIlv[3KnYYPld{BmgHC{ZYPzbY9vKG:owrDWSWdHWjQEoH3SUmE> MViyOFcyODZ|MR?=
HeLa NIDX[ndHfW6ldHnvckBCe3OjeR?= MmPwNY1O NYfpWXNNOC53aB?= NUHYRoR{[WKxbHnzbIV{KHSqZTD0c5RidCCKRFHDJIFkfGm4aYT5 MYOyOFcxPzR5NB?=
ACP02 NGHQ[WdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnaNlUxNzN3MD:1NFBvVQ>? M173U|I1cA>? M325bYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDv[kBieHC{b4jpcYF1\Wy7IEewxsAmKGG2IEK1NOKhdk1? NEm1V4wzPDZ4OEW0Oy=>
ACP03 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PtR|I2OC9|NUCvOVAxdk1? NFnXXWozPGh? M16xeoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDv[kBieHC{b4jpcYF1\Wy7IEewxsAmKGG2IEK1NOKhdk1? MYiyOFY3QDV2Nx?=
U87 GBM MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DBRVExOC9|MECvOVAxKG6P MYe3NkBp NGfOTZMyODBnIHX0bIFvd2x? MmXRdoVlfWOnczDt[YFvKGOnbHygcpVu[mW{IHL5JFMyNCB3NDygZY5lKDV6wrCl MXeyOFQ3PDh2MR?=
U87 GBM NFfGZ4pHfW6ldHnvckBCe3OjeR?= NFLBcWcyODBxNUCwJG5u Ml2zOFghcA>? NHzLSHQyODBnIHX0bIFvd2x? MmriTY5lfWOnczDT[Y5me2OnbnPlMWxqc2ViQXz0[ZJifGmxboOgbY4hVnWlbHXhdkBOd3KyaH;sc4d6 MnXXNlQ1PjR6NEG=
RPE NHHZeI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7XO2hROC5{L{CuOE8xNjhxMTFOwG0> NXfZdZQxOjRxNEivO|IhcA>? MnLtSG1UVw>? NWfzWIx2cW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44h[nliY3XscEBkgWOuZTDhdpJme3R? M4rGTFI1PDV4NkCy
HT29  M2L2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rVNVE5OCCwTR?= NFrCdYE4OiCq NX:2fWhPUUN3MDDv[kAyQDBibl2= NFTkT5QzPDN4OEK2OS=>
hMSCs NFTlTGhHfW6ldHnvckBCe3OjeR?= NHzNXno3NjJ3IH7N MnfUNlQhcA>? MVnEUXNQ NETTWmJ{fGGkaXzpfoV{KEirc4TvcoUhSWOndInsZZRqd25iYX7kJJRp\SCHeIDy[ZN{cW:wIH;mJHBtfXKrcH;0[Y51KEenbnXz M4LuSVI1OzF{M{W2
Huh7  MlvFSpVv[3Srb36gRZN{[Xl? MVOwMlEwOC53L{GuNEDPxE1? MknUNlRp M3LhS5N2eHC{ZYPz[ZMhYVSKRFOyJIdmdmViZYjwdoV{e2mxbh?= NXvETYx6OjR{Nkm2O|I>
SKOV3 MmPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvGOIQxNjB3LUKg{txO Ml7KNVAwOjRxNEigbC=> Ml75SG1UVw>? M4P6Wo1m\GmjdHXzJIdzd3e2aDDhdpJme3RiaX6gZUBkd26lZX70doF1cW:wLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ MYmyOFIzOzhyMR?=
A2780 M{nxbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjaTIZUOC5yNT2yJO69VQ>? M2T5ZlExNzJ2L{S4JIg> NUDqOZp6TE2VTx?= NXHPcWF2dWWmaXH0[ZMh\3Kxd4ToJIFzemW|dDDpckBiKGOxbnPlcpRz[XSrb36tJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= MonVNlQzOjN6MEG=
SRA01/04  MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXywMlIh|ryP NEm1[Iw1QCCq M4TUbWROW09? MoTOd5VxeHKnc4Pld{Bk\WyuIIDyc4xq\mW{YYTpc44hfGi{b4XnbEB{fXCycnXzd4lv\yC2aHWgVGk{Uy:Da4SsJJA{QE2DUFugZY5lKEWUS{GvNkB{cWewYXzpcocheGG2aIfhfZM> MYiyOFE2Pzh5OB?=
HLEB3 NV;OZYxTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYX5UnlUOC5{IN88US=> NGHkR3M1QCCq MVrEUXNQ MoXEd5VxeHKnc4Pld{Bk\WyuIIDyc4xq\mW{YYTpc44hfGi{b4XnbEB{fXCycnXzd4lv\yC2aHWgVGk{Uy:Da4SsJJA{QE2DUFugZY5lKEWUS{GvNkB{cWewYXzpcocheGG2aIfhfZM> M1rXeVI1OTV5OEe4
SRA01/04  M1S1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEiwcWgxNjRxMD64JO69VQ>? NIrVcmE1QCCq NF7FOmVFVVOR M{HwPIlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MXGyOFE2Pzh5OB?=
HLEB3 NX3V[ogzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTvNE41NzBwODFOwG0> NFTzdHM1QCCq NFu1OnZFVVOR MWrpcoR2[2W|IHPlcIwh[XCxcITvd4l{ NVL2SoU3OjRzNUe4O|g>
HCT116 NXfIfHVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYH5NldTOC5{IN88US=> MlvDNVIhcA>? MVTlcohidmOnczDj[YxtKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IILh[IlifGmxbh?= NGnCVVEzPDF{MkKzNS=>
CA46 Mo\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnL6N{83NzF{L{K0M|Q5KG6P M1r2S|Q5KGh? NYqxU4h2cW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbjDheEAzPCCjbnSgOFghdk4EoB?= M1fBWlI1ODZ2OUWx
PMNs MUPGeY5kfGmxbjDBd5NigQ>? NHP4V4s{OCCwTR?= NFT2NoU1QCCq MX7pcohq[mm2czDl[oZmem:leYTvd4l{NCCKRFHDJIFkfGm4aYT5JIFv\CCUYXOgZYN1cX[rdIm= NHH1Zm0zOzl6OE[xOy=>
H1299 NF7jb5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorwNeKh|ryPwrC= NH2zTY0zPC92OD:3NkBp M1uzOYV1cGGwb3y= MX;pcoNz\WG|ZYOgZ4VtdCCmZXH0bEBi\nSncjCyOIg> MlnNNlM6OTZ4MEm=
A549 NHTrW5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIf3c5YxNjJ3L{CuOU8yKM7:TR?= NGW2clYzPC92OD:3NkBp NH\KcZpmfGijbn;s NIfz[2hqdmirYnn0d{B1cGViY3XscEBoem:5dHigbY4h[2:wY3XueJJifGmxbjDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ MlniNlM5Pjd7OUG=
H1299 MorGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvkNE4zPS9yLkWvNUDPxE1? MkTFNlQwPDhxN{KgbC=> MYrleIhidm:u M37qV4lvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDpckBkd26lZX70doF1cW:wIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? M132dVI{QDZ5OUmx
A549 MVvBdI9xfG:|aYOgRZN{[Xl? M3PiS|AvPS9zIN88US=> NVzTRY1IPDhiaB?= NX3DeoRz\XSqYX7vcC=> NWS2S3dPcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MmTyNlM5Pjd7OUG=
H1299 MkO2RZBweHSxc3nzJGF{e2G7 MoXyNE42NzFizszN NX;Zc4tvPDhiaB?= NGD3OGZmfGijbn;s MmHZbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? Mn\LNlM5Pjd7OUG=
SUM149PT MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTtNk84NjVxMUCg{txO NVvVPZM6PDhiaB?= MnK0SG1UVw>? NEXVfmtqdmS3Y3XzJINmdGxiZHXheIgh[XRiMjFOwG0hcW6|ZX7zbZRqfmWueR?= NIDycpAzOzd7Mk[zPC=>
SUM190PT NIHMXZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVG2d|dbPTBxMUCwM|I2OCCwTR?= MlfnOFghcA>? MVvEUXNQ NFH1d5hqdmS3Y3XzJINmdGxiZHXheIgh[XRiNUCgcm0he2Wwc3n0bZZmdHl? NWXoeHlbOjN5OUK2N|g>
HCT1 M{DBWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3j3dVAvOi9zLkCvOU4xKM7:TR?= MVixNk8zPC9|Nj:0PEBp MUPpcoR2[2W|IHPlcIwh\GWjdHigbY4h[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= MlnlNlM4PzByMEC=
Lovo MnfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnLS4s4OC5{L{GuNE82NjBizszN Mn7iNVIwOjRxM{[vOFghcA>? NH3tRWtqdmS3Y3XzJINmdGxiZHXheIghcW5iY3;uZ4VvfHKjdHnvck0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> M{PMelI{PzdyMECw
AGS NWPtTYlST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXywMlAyPS1zIN88US=> Mn:wO|IhcA>? Mn;xbY5lfWOnczDj[YxtKGSnYYToJINwdmOnboTyZZRqd25iZHXw[Y5l\W62bIm= M{PR[lI{PzR3MEK0
Huh7 MlLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIr6Vo0yKM7:TR?= NUjtR3hjOjRiaB?= MUPEUXNQ NWjvW2VJemWmdXPld{Bi[m:3dDCyNEUhfmmjYnnsbZR6yqB? MlL0NlM3PDN7M{O=
ECC1 MofjSpVv[3Srb36gRZN{[Xl? NEHvR|g2ODBibl2= NIXOTVE2KGR? NFXHbHpFVVOR MlXSbY5lfWOnczDMNWNCVcLiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1MWF7[UN? Mk\oNlM2OzB5Nkm=
HEC1A M{\pc2Z2dmO2aX;uJGF{e2G7 NYC4fWhnPTByIH7N MYW1JIQ> M4S2UWROW09? NFLNTWtqdmS3Y3XzJGwyS0GPwrDlfJBz\XO|aX;uJINwNXS{ZXH0cYVvfCC5aYToJFUuSXqjQx?= MoXsNlM2OzB5Nkm=
EN1 MmfHSpVv[3Srb36gRZN{[Xl? MY[1NFAhdk1? NWi1WYhTPSCm MW\EUXNQ Mk[0bY5lfWOnczDMNWNCVcLiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1MWF7[UN? MUCyN|U{ODd4OR?=
MFE296 M{i4d2Z2dmO2aX;uJGF{e2G7 MUK1NFAhdk1? NV7sR3A4PSCm NIXRZ5hFVVOR MkL3bY5lfWOnczDMNWNCVcLiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1MWF7[UN? NYDTXJM2OjN3M{C3Olk>
HASMCs NFvVNJFHfW6ldHnvckBCe3OjeR?= M3LCUlAuPTByIH7N NGf2V2c3KGR? NUnzXWUy\G:5bj3y[Yd2dGG2ZYOgeIhmKGW6cILld5Nqd25ib3[gTGFFSyCjbnSgZ4VtdCC4aXHibYxqfHl? Mn7zNlM2OTh2Nke=
U373 NHvKW2FHfW6ldHnvckBCe3OjeR?= MVywMlI2NzBwNT:xJO69VQ>? M3;Q[VI1KGh? NWqzZ25ocW6lcnXhd4V{KFCULVKg[ZhxemW|c3nvckBkdy22cnXheI1mdnRid3n0bEA2SXqjZFO= NUS5c297OjN2N{SxO|E>
ARN8  NHnyNWVHfW6ldHnvckBCe3OjeR?= NIj4NpExNjB3LUKg{txO MYKyOEBp MnK3doVlfWOnczD0bIUhcW6mdXP0bY9vKG:oIIC1N{1l\XCnbnTlcpQh\2WwZYOgZpkhVnW2bHnuMVM> NUHVOIpxOjN2N{C1OFA>
MCF7 MlvjSpVv[3Srb36gRZN{[Xl? M1nH[|AvODVvMjFOwG0> MkfENlQhcA>? NX\vTIZFemWmdXPld{B1cGViaX7keYN1cW:wIH;mJJA2Oy2mZYDlcoRmdnRiZ3Xu[ZMh[nliToX0cIlvNTN? NUf1UYpqOjN2N{C1OFA>
H1299  MX7GeY5kfGmxbjDBd5NigQ>? Mlj2NE4{O+LCk{JCpOK2VQ>? NHixW4czPC92ODDo MoqzSG1UVw>? MmPobY5kemWjc3XzJGUu[2GmaHXybY4heHKxdHXpckBt\X[nbIOg[I9{\SCmZYDlcoRmdnSueR?= MVSyN|Q3OTl5NR?=
H1299 M3\kNWZ2dmO2aX;uJGF{e2G7 MkntNE42KM7:TR?= NY\ZSJA4PDhiaB?= NI\PPVdFVVOR M1XqfolvcGmkaYTzJJRp\SCvaXfyZZRwenlicH;0[Y51cWGuIHPvcYJqdmVid3n0bEB{cWyrYnnubY4> NGq5dlYzOzR4MUm3OS=>
H1299 NXm5b5M6TnWwY4Tpc44hSXO|YYm= NWXreHpNOC53IN88US=> M3zxeFQ5KGh? MYHEUXNQ NIrWSFJqdmirYnn0d{B1cGViaX72ZZNqfmWwZYPzxsAh[2:vYnnu[UB4cXSqIIPpcIljcW6rbh?= NWfqTXVTOjN2NkG5O|U>
MG-63  Ml\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{T3fFAvOyEQvF2= MnXsNVIuQTZiaB?= MXXEUXNQ NED0XXlqdmirYnn0d{B1cGViY3XscEBoem:5dHigZ48ufHKnYYTt[Y51KHerdHigcYV1\m:{bXnu MVWyN|Q2OThzNx?=
LM8 Ml3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjnT3QxNjNizszN MWCxNk06PiCq MofJSG1UVw>? MlLNbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIHPvMZRz\WG2bXXueEB4cXSqIH3leIZwem2rbh?= M3XP[VI{PDVzOEG3
K562 MYDGeY5kfGmxbjDBd5NigQ>? NEDNdYExNjVizszN MkTyNlQhcA>? Mmrs[ZRp[W6xbB?= M1\0bYRm[3KnYYPld{B1cGViZX76fY1mKGGldHn2bZR6KG:oIFjERWN{KGOxLYTy[YF1dWWwdDD3bZRpKGO3cnP1cYlv Mnu3NlM1OzB7NUe=
HEL M2ThS2Z2dmO2aX;uJGF{e2G7 MW[wMlUh|ryP MlfENlQhcA>? NYTnTHRs\XSqYX7vcC=> MYjk[YNz\WG|ZYOgeIhmKGWweont[UBi[3Srdnn0fUBw\iCKRFHDd{Bkdy22cnXheI1mdnRid3n0bEBkfXKldX3pci=> NVfOb4JFOjN2M{C5OVc>
HL60 NVfa[YF7SXCxcITvd4l{KEG|c3H5 MYSxJO69VQ>? MUiyOEBp NFjYdXdqdmS3Y3XzxsBk\WyuIHTlZZRp M3LUbFI{PDByNUG5
KG1 NEHYfWNCeG:ydH;zbZMhSXO|YYm= NFzab|gyKM7:TR?= NXvrdlFqOjRiaB?= M4\YeIlv\HWlZYRCpINmdGxiZHXheIg> MWiyN|QxODVzOR?=
Kazumi NHnj[lFCeG:ydH;zbZMhSXO|YYm= NWDwV5o5OSEQvF2= M{nNflI1KGh? NVvpT|NucW6mdXPld:Kh[2WubDDk[YF1cA>? MkLxNlM1ODB3MUm=
K562 MUTBdI9xfG:|aYOgRZN{[Xl? M4LWcFEh|ryP NIfHSJgzPCCq NFm2Z5FqdmS3Y3XzxsBk\WyuIHTlZZRp NHLKPIQzOzRyMEWxPS=>
THP1 NFHNXG1CeG:ydH;zbZMhSXO|YYm= NVXIWpFLOSEQvF2= M1LubVI1KGh? NUHXbIVzcW6mdXPld:Kh[2WubDDk[YF1cA>? MniwNlM1ODB3MUm=
SH-SY5Y MV7GeY5kfGmxbjDBd5NigQ>? NIHhclEzPTBibl2= MlfNNVYhcA>? MoLmZ4hidmenczDlfJBz\XO|aX;uJJBifHSncn6gc4Yh\2WwZYOgbY53d2y4ZXSgbY4h[2ixbHXzeIVzd2xic4nueIhme2m|LDD1dJRic2ViYX7kJIVn\my3eB?= MmO0NlM{OjZ2MkK=
HEK293 M{jteWZ2dmO2aX;uJGF{e2G7 MVGxJOK2VcLi NFLPVGQyQCCqwrC= NVzEfIRXcW6qaXLpeJMhfGinIHvhcIlzcW5vNz3t[YRq[XSnZDDy[YNzfWm2bXXueEBw\iC|eX7wbIltcW5vMTDh[4dz\WejdHXzJIlvfG9iYXfndoV{d22ncx?= NX3aOnBqOjN{OES4OFg>
HTK MlnESpVv[3Srb36gRZN{[Xl? NX\IPGZQPDByIH7N NHPocHc4OiCq MVPpcohq[mm2czDUS2Yu|rMkgKPJcoR2[2WmIF35c4Zq[nKxYnzhd5QhTGmoZnXy[Y51cWG2aX;u MWKyN|I5PDByMh?=
HTK NFvGSmVHfW6ldHnvckBCe3OjeR?= NGj2N3oyODBvOECwcm0> MnLvO|IhcA>? NIW1N2NjdG:la4OgWGdHNc7{4pETTY5lfWOnZDDSU3Mh[W6mIFiyU|LDqEGlY4XteYxifGmxbh?= M{ny[FI{Ojh2MECy
Caco-2  NH7mNFJHfW6ldHnvckBCe3OjeR?= NHXoNXoyKML3TdMg MWCyOEBp NUf1boNz\GWlcnXhd4V{KFOHUmSgdJJwfGWrbjDlfJBz\XO|aX;u MmTlNlMyQTVyN{C=
HeLa MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;lXZN5OTByIH7N NXn4dIdiOjRiaB?= M2H0PGROW09? M{TwTGlEPTBib3[gNVAxdk1? NH7YeVYzOzF4NUe0PC=>
HeLa NYrQdYVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYe0NEBvVQ>? M2LKe|Q5KGh? MmX4SG1UVw>? M17hSmlEPTBib3[gOFBvVQ>? NF\3[IIzOzF4NUe0PC=>
HeLa NWnYV5M4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDLVJgzOCCwTR?= NWTPcpB2PzJiaB?= M2XIOGROW09? NVn2VlBlUUN3MDDv[kAzOG6P NHPHVHkzOzF4NUe0PC=>
HeLa NGrldWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWWxNE8{OC93MDDuUS=> NUS2VYwxPzJiaB?= MnjPSG1UVw>? NGK5SHJqdmO{ZXHz[ZMhfGinIH71cYJmeiCxZjDNUXAhMM7WzrjtLUBtd3O|IHPlcIx{KGSxc3Wg[IVx\W6mZX70cJk> M4XwelI{OTZ3N{S4
MDA-MB-231 NHHQdIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PWTlI2NTRyMDDuUS=> NXu4UYdoPDhiaB?= M2f3O2lEPTBib3[gNlY{NjKwTdMg NFSy[2QzOzB3NUG5PC=>
MCF-7  NV;CUXdDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHRfoo6OjVvNECwJI5O NGTDdmY1QCCq MXjJR|UxKG:oIEKyNE41dk1? MnjnNlMxPTVzOUi=
ECC-1  MnjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWqxNFAhdk1? NYflS2ZLOjRiaB?= NGG1fHVmfGijbn;s MorjbY5kemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJIFxd3C2b4TpZ{BvfWOuZXmgeI8hOzVn MlrKNlMxOjh6MEO=
HEC-1A NEm4UFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUGxNFAhdk1? NWPreJN3OjRiaB?= M17RToV1cGGwb3y= MoWxbY5kemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJIFxd3C2b4TpZ{BvfWOuZXmgeI8hOzln M{PxOVI{ODJ6OECz
NHAC-kn MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWmxNE8yODBxNUCwJI5O NWj6eHI3OTJiaB?= NGL3O5ZFVVOR MlvnTWM2OCCxZjC1NFBvVQ>? Mki3NlMxOTd6N{G=
A549 NWHsWpV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUKyOVAhdk1? NFzpfHI3NTd{IHi= NXrCRXFmTE2VTx?= M4DRdoNifXOnczDhJIdz\WG2ZYKgbY5pcWKrdH;yfUBm\m[nY4SgZ49u[mmwZTD3bZRpKFS[VDDvdkBmemyxdHnubYI> MmLINlI6QTR5OEC=
MG-63 NILQSllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXmzNFAhdk1? NWXySY1jOTJiaB?= MkfzSG1UVw>? NGfjRoNqdmirYnn0d{B1cGViY3XscEBoem:5dHigeI8hQDZn NGLwfHQzOjd7OUOzPC=>
MG-63 M3XPcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTsN|AxKG6P MXiyOEBp MVjEUXNQ M3G1eIlvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDD0c{A3PyV? Mn\iNlI4QTl|M{i=
MG-63 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEL2fII{ODBibl2= NGLtOlU1QCCq NWPpPHN2TE2VTx?= MnP3bY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIITvJFU3LQ>? NITz[JgzOjd7OUOzPC=>
HL60  MkO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7jelEyPTBvM{WwJI5O NX;ZVW5YOjRiaB?= NEf2UpNqdmO{ZXHz[ZMh[2WubDDhdI9xfG:|aYRCpJdp\W5iY3;uZ4VvfHKjdHnvcpMhcGmpaHXyJJRp[W5iMkWwJI5O NID3NZozOjd3M{ezPS=>
U937 NXzFbm54T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fCUFE2OC1|NUCgcm0> NYjGeppwOjRiaB?= MYHpcoNz\WG|ZYOgZ4VtdCCjcH;weI9{cXQEoIfo[Y4h[2:wY3XueJJifGmxboOgbIlocGW{IIToZY4hOjVyIH7N NX\Eb|IxOjJ5NUO3N|k>
SCC-6 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HvSFIxOC1|MkCwJI5O M4TpPVEzNzJ2L{S4JIg> NH7OOmVFVVOR MVfpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDv[kBUS0NvNjDj[YxteyCrbjDhJIRwe2VvIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? MU[yNlU2OjN{MR?=
U87  M4XnXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjpUFkyODBvM{CwJI5o NXO3TYRUOjRiaB?= M1z6[4lvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDD0c{A4OiViIHH0JFIxOG6p NXjsbGdDOjJ{N{C4OFk>
K562 M{jIeWZ2dmO2aX;uJGF{e2G7 MmLiNUDPxE1? M1XENVEzKGh? MoqxSG1UVw>? M3TiO4VvcGGwY3XzJJRp\SCneIDy[ZN{cW:wIH;mJHJWVlh|IHnu[JVk\WRiYomgOU1igmFvQ3TS MUCyNlE4QTF7OB?=
Reh Mn61SpVv[3Srb36gRZN{[Xl? NVPn[Gs3OC5|L{Gg{txO M1nZRlEzKGh? M37iZ2ROW09? Mn3K[Y5p[W6lZYOgeIhmKGW6cILld5Nqd25ib3[gVnVPYDNiaX7keYNm\CCkeTC1MYF7[S2FZGK= MnGzNlIyPzlzOUi=

... Click to View More Cell Line Experimental Data

体内研究 Administration of Trichostatin A 按 0.5 mg/kg 剂量处理N-甲基-N-亚硝基脲致癌物诱发的大鼠乳腺癌模型,持续处理4周,具有有效的抗癌活性,即使按按高达5 mg/kg剂量处理也没有任何可测量到的毒性。[1]Trichostatin A 按10 mg/kg 剂量单独腹腔注射给药非转基因和脊髓性肌萎缩症(SMA)模型鼠,导致乙酰化的 H3 和 H4组蛋白水平提高,也导致活运动神经元(SMN) 基因表达稍微提高。Trichostatin A 每天按10 mg/kg剂量处理SMA模型鼠,促进存活, 减轻体重下降,且增强运动行为。[5]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
+ 展开

体外HDAC活性 :

从每种乳腺癌细胞系(MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51,或 SK-BR-3)中准备全部细胞提取物。在溶于0.1% (v/v)乙醇的不同浓度Trichostatin A存在时,或者使用0.1% (v/v)乙醇作为对照, 20 μL 细胞粗提取物(~2.5 ×105 个细胞)与 1 μL ~1.5 × 106 cpm [3H]乙酰标记的组蛋白 H4 肽底物(第2-20位NH2-末端残基) 在25oC下温育60分钟。使用50 μL 1 M HCl/0.16 M 乙酸对每组 200-μL 反应进行淬火,然后使用600 μL 乙酸乙酯进行抽提,通过闪烁计数器测量释放的[3H]乙酸。使用非线性回归曲线拟合抑制数据,绘制合适的剂量反应曲线,而测定IC50。
细胞实验:[1]
+ 展开
  • Cell lines: MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, 和 SK-BR-3
  • Concentrations: 溶于无水酒精,终浓度为~10 μM
  • Incubation Time: 96小时
  • Method: 使用不同浓度Trichostatin A处理细胞96小时。处理后,使用sulforhodamine B 比色分析测定细胞增殖。通过台酚蓝染色排除法测定细胞活力。
    (Only for Reference)
动物实验:[1]
+ 展开
  • Animal Models: 携带NMU诱导的肿瘤的近交系(Ludwig/Wistar/Olac)处女鼠
  • Formulation: 溶于DMSO
  • Dosages: ~5 mg/kg/day
  • Administration: 皮下注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 23 mg/mL (76.05 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
3mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 302.4
化学式

C17H22N2O3

CAS号 58880-19-6
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02959905 Recruiting Metastatic Melanoma BGI China|Sun Yat-sen University December 2016 Phase 1
NCT03133819 Enrolling by invitation Diabetes; Neuropathy Polyneuropathy (Manifestation) Chang Gung Memorial Hospital November 2016 Not Applicable
NCT02486965 Recruiting Fibromyalgia University Hospital Brest October 2015 Not Applicable
NCT01954433 Active not recruiting Glenohumeral Arthritis and/or Rotator Cuff Tear Arthropathy (TSA)|Rotator Cuff Tear (RCR)|Trapeziometacarpal Osteoarthritis (TMC OA) Matthias Flury|Winterthur Institute of Health Economics (WIG) Switzerland|Schulthess Klinik November 2013 --
NCT01575106 Completed Pain Massachusetts General Hospital June 2012 Not Applicable
NCT02762903 Completed Osteoarthritis Columbia University August 2009 Not Applicable

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    I would like to obtain the enantiomers of TSA, as separate chemicals: R-TSA and S-TSA. Do you have any ideas?

  • 回答:

    Our S1045 Trichostatin A (TSA) is R enantiomer.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

相关HDAC产品

Tags: 购买Trichostatin A (TSA) | Trichostatin A (TSA)供应商 | 采购Trichostatin A (TSA) | Trichostatin A (TSA)价格 | Trichostatin A (TSA)生产 | 订购Trichostatin A (TSA) | Trichostatin A (TSA)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID